explore -WSS

explore

author：entertainment 2025-09-28 00:48:16 - browse：661

Verve Therapeutics said Sunday that the first 10 people to receive a one-time treatment powered by a form of CRISPR called base editing showed reductions in bad cholesterol levels — study results that are preliminary but signal the potential for gene-editing treatments to benefit people with an inherited type of cardiovascular disease.

Three of the study participants treated with potentially therapeutic doses of the Verve drug, called VERVE-101, showed reductions in LDL-C levels of 39%, 48%, and 55%, respectively. The latter patient’s decline in so-called “bad” cholesterol was maintained for six months.

The Verve-101 study results were presented at the American Heart Association conference and are the first data in patients from a therapy that uses base editing to change individual letters of DNA. Verve licensed the base-editing technology from Beam Therapeutics.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： HHS names first

focus

WSS

How I ended up pumping milk in a bathroom stall at JPM 2024

Election results set back Medicaid expansion plans

Pennsylvania man bitten on the head by bear during attack in his garage

Trump used to be more articulate. What could explain the change?

Why liver experts renamed NASH to MASH, and NAFLD to MASLD

It was time to plan for my old age. If only I could stop crying

leisure time

explore

hotspot

Medical leaders decry Supreme Court decision on affirmative action

The nurse manager staffing crisis is hurting patients

Activists slam private health insurers over coverage restrictions

GSK to buy asthma

Duchenne breakthrough therapy leaves behind pioneering families

How I ended up pumping milk in a bathroom stall at JPM 2024

Moonlake's readout produced a cash windfall. Risks remain

Democrats are overperforming in 2023's special elections. Is it a clue for Biden vs. Trump?

Supreme Court strikes down use of affirmative action

HHS names first

focus

The SUPPORT Act is critical to fighting the opioid crisis

Feed a cold, starve a fever? Here’s what science says

'Brian's Song' at 50 still offers lessons about cancer for today

Doulas covered by Medicaid under New York's new plan

Risky weight loss products often used by teens globally, per study

Fauci’s Covid grilling leads GOP to weigh foreign research rules

focus

focus

focus

focus